Literature DB >> 19105233

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.

Eduardo Arellano-Rodrigo1, Alberto Alvarez-Larrán, Juan-Carlos Reverter, Dolors Colomer, Neus Villamor, Beatriz Bellosillo, Francisco Cervantes.   

Abstract

Patients with essential thrombocythemia (ET) have an increased frequency of thrombosis, but the relationship of both thrombosis and JAK2 V617F allele burden with platelet turnover, acquired activated protein C resistance (aAPCR), and levels of coagulation factors and soluble markers of platelet, and endothelial activation is not well known. In 53 ET patients (26 with a history of thrombosis), reticulated platelets (RP) percentage, aAPCR, platelet tissue factor (TF) expression, and plasma levels of TF, coagulation factors, soluble P-selectin (sP-selectin), soluble CD40 ligand (sCD40L), von Willebrand factor antigen (VWF:Ag), soluble thrombomodulin (sTM), D-dimer and prothrombin fragment 1 + 2 were compared with those in matched healthy individuals and correlated with thrombosis occurrence and JAK2 mutational load. ET patients with thrombosis had significantly higher values for RP percentage, aAPCR, and levels of factors V and VIII, VWF:Ag, sP-selectin, and sCD40L than patients without thrombosis and controls. At multivariate study, RP percentage, factor V levels, and aAPCR were independently associated with an increased risk of thrombosis. Patients with JAK2 mutation had significantly lower levels of free protein S (PS) and higher levels of TF, sP-selectin, sCD40L, VWF:Ag, and sTM than those with wild-type allele. A mutant allele dosage effect (>or= 12%) was observed for TF, sP-selectin, sCD40L, VWF:Ag, and PS levels. These results support a role for platelet turnover, factor V, and aAPCR in the thrombosis of ET as well as the association between JAK2 V617F allele burden and either decreased free PS or increased TF and soluble markers of platelet and endothelial activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19105233     DOI: 10.1002/ajh.21338

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  29 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  Blood cell activation in myeloproliferative neoplasms.

Authors:  Francisco Cervantes; Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Authors:  Lamia Lamrani; Catherine Lacout; Véronique Ollivier; Cécile V Denis; Elizabeth Gardiner; Benoit Ho Tin Noe; William Vainchenker; Jean-Luc Villeval; Martine Jandrot-Perrus
Journal:  Blood       Date:  2014-06-20       Impact factor: 22.113

4.  Lysyl oxidase is associated with increased thrombosis and platelet reactivity.

Authors:  Shinobu Matsuura; Rongjuan Mi; Milka Koupenova; Alexia Eliades; Shenia Patterson; Paul Toselli; Jonathan Thon; Joseph E Italiano; Philip C Trackman; Nikolaos Papadantonakis; Katya Ravid
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

5.  The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.

Authors:  Youwen Qin; Xiaorui Wang; Chuxian Zhao; Chun Wang; Yining Yang
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

6.  A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Authors:  Claire Pluchart; Coralie Barbe; Gael Poitevin; Sandra Audonnet; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

7.  Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Authors:  Marina Marchetti; Carmen J Tartari; Laura Russo; Marina Panova-Noeva; Annamaria Leuzzi; Alessandro Rambaldi; Guido Finazzi; Barry Woodhams; Anna Falanga
Journal:  Am J Hematol       Date:  2013-11-20       Impact factor: 10.047

8.  JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Authors:  Bärbel Edelmann; Nibedita Gupta; Tina M Schnoeder; Anja M Oelschlegel; Khurrum Shahzad; Jürgen Goldschmidt; Lars Philipsen; Soenke Weinert; Aniket Ghosh; Felix C Saalfeld; Subbaiah Chary Nimmagadda; Peter Müller; Rüdiger Braun-Dullaeus; Juliane Mohr; Denise Wolleschak; Stefanie Kliche; Holger Amthauer; Florian H Heidel; Burkhart Schraven; Berend Isermann; Andreas J Müller; Thomas Fischer
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

9.  Acute splenic infarction presenting as an unusual manifestation of essential thrombocythaemia with normal platelet count.

Authors:  Katsuyuki Yoshida; Ibuki Kurihara; Takahiko Fukuchi; Hitoshi Sugawara
Journal:  BMJ Case Rep       Date:  2019-07-03

Review 10.  Cerebral thrombosis and myeloproliferative neoplasms.

Authors:  Andrea Artoni; Paolo Bucciarelli; Ida Martinelli
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.